TrialInternational journal of rheumatic diseases2021

Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy.

Xiaofeng Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.